Expert Highlights Key Topics of Discussion at the 15th Annual New York Lung Cancers Symposium
Mark G. Kris, MD, discusses 1 of the major topics of discussion from the 15th Annual New York Lung Cancers Symposium, among other areas of focus at the meeting.
Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses 1 of the major topics of discussion from the 15th Annual New York Lung Cancers Symposium, among other areas of focus at the meeting.
One of the key messages at this year’s meeting is that coronavirus disease 2019 (COVID-19) is now another complication of lung cancer, says Kris. The discussions during this meeting will focus on some very important issues in lung cancer, and at this time, COVID-19 has become a threat for patients with lung cancer that needs to be addressed.
Kris says that all but 2 of his patients with lung cancer died from the cancer as opposed to COVID-19, so this demonstrates it is a threat to patients that needs to be managed. This is an important topic at this year’s meeting, among others that will address new therapeutic approaches and emerging technologies in the lung cancer space.
Everolimus Plus Lanreotide Shows PFS Benefit in Unresectable/Recurrent GEP-NETs
January 21st 2025The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
Read More
Kim Evaluates New Regimens for EGFR+ Lung Cancer
January 20th 2025During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and MARIPOSA trials of newer regimens for EGFR-positive lung cancer.
Read More
Amivantamab/Lazertinib Maintains OS Benefit in EGFR+ NSCLC
January 15th 2025During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung cancer in the second article of a 2-part series.
Read More
